MLN 2222

Drug Profile

MLN 2222

Alternative Names: CAB-2; CMI-CAB-2; MLN2222; MLN2222 CAB-2

Latest Information Update: 08 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer XOMA
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Inflammation; Reperfusion injury

Most Recent Events

  • 14 May 2008 Takeda acquires Millennium Pharmaceuticals
  • 20 Mar 2006 XOMA has completed a phase I trial in the US
  • 05 Aug 2005 This compound is still in active development - (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top